A carve-out isn't a transaction. It's a company build.
Large corporations hold technologies with massive commercial potential that will never be realized inside the existing organization. Different strategic priorities, internal politics, resource constraints — the reasons vary, the result is the same: valuable IP sits unused.
mantro's Carve-Out Factory identifies these hidden gems and turns them into market-ready, independently funded companies — with you as a strategic minority shareholder, not the operator.
Why brilliant tech dies inside large corporations
Strategic misfit
The technology is real, but it doesn't fit the P&L of any business unit. No one owns it long enough to push it to market.
Resource gravity
Operating businesses absorb every available engineer, dollar, and quarter of management focus. Long-cycle innovation loses by default.
Risk asymmetry
Inside the company, the cost of trying is visible and the upside is uncertain. Outside, the math flips — capped downside, equity upside, and someone else builds it.
The talent problem
The people best placed to commercialize the technology rarely want to run it inside the parent. They want a venture, founder equity, and a clean slate.
Executives know the problem. Few solve it inside.
Innovation isn't a strategy gap — it's an execution gap. The decision has been made at the top, the spend is on the books, and the result still disappoints. The cost isn't visible on the P&L: it's the IP that never reaches the market, the founders who leave, the M&A targets you end up buying back later at venture valuations.
84% of executives
6% are satisfied
45% of global PE deal value
Monetize dormant IP without selling it
Carve-outs convert R&D balance-sheet weight into venture equity. The corporate retains a minority stake, captures upside at venture-grade valuations, and avoids the discounts and tax friction of a straight IP sale.
Free management bandwidth for the core
Promising but non-core technologies pull focus from the businesses that actually pay the bills. A carve-out moves the technology to a structure that's built for it — and gives the executive team back the quarters they were spending defending the project internally.
Off-balance-sheet innovation
Phase 1 of the carve-out is funded by your internal innovation program. From Phase 2 onward, the venture is funded by external investors at a venture-grade valuation. Future growth doesn't sit on your P&L. The upside still does — through equity.
IP integrity and licensing control
Carve-out structuring defines exactly what transfers, what is licensed, and on what terms. You keep the IP you want to keep, license the rest with field and territory restrictions, and stay in control of the technology's commercial direction.
Build the M&A target you'd rather not buy back later
Five years from now, the technology you didn't commercialize will be sold by someone else — back to you, at a multiple. Carving out today means a strategic right to re-engage tomorrow, on terms you defined.
Continued collaboration with the inventors
The founding team carries the technology forward, but the link back to the corporate lab stays open — joint development, advisory roles, supply or pilot partnerships. The science doesn't leave your orbit; it gets a structure built around it.
From corporate R&D to operating company — a structured two-phase process
-
Venture Readiness (~20–24 weeks)
We analyze the technology, map the commercialization pathway, identify the founding team, design the ownership and licensing structure, develop the investor narrative, and prepare the legal carve-out. By the end of this phase, the venture thesis is built and investors are engaged.
-
Venture Formation
We incorporate the venture, execute the IP transfer, finalize fundraising, complete the cap table, and launch the company with a full founding team and governance structure.
mantro co-invests directly. We don't just build the venture — we back it with our own capital.
What a carve-out does to the parent company
The carve-out isn't only about the venture. It's about what changes inside the corporation while the venture is being built — and after.
For talent. The best people in your R&D, strategy, and innovation teams want to be near work that has consequence. A live carve-out is a visible signal that this company moves IP to market — not just to slide decks. It attracts the kind of internally entrepreneurial talent every large company complains it can't keep.
For internal innovation appetite. Once one carve-out runs cleanly, the next is easier. Project leads have a real destination for breakthrough work that doesn't fit a P&L. Sponsorship conversations get shorter. The "where could this even go?" question gets a defined answer.
For board-level credibility. Boards reward visible portfolio thinking. A working carve-out is a low-cost, high-narrative proof point — capital-efficient, externally validated, with a real founding team and clean governance. It tells a story about the company that's hard to tell with internal projects alone.
For the brand. The venture's customers, investors, and press become a second channel telling your company's innovation story — credibly, because they have skin in the game.
Benefits
For Corporates
- Minority equity stake — upside without operational burden
- Growth funded by venture investors, not your balance sheet
- Pre-defined right to strategic re-engagement (license, partner, acquire)
For Investors & PE
- Access to pre-validated deep tech ventures — not raw deal flow
- Every venture arrives with: structured IP, tested market thesis, assembled founding team, clear governance
- mantro as co-founder and co-investor — permanent skin in the game
- Plug-and-play infrastructure: the venture is operational from day one
Benefits
For Corporates
- Minority equity stake — upside without operational burden
- Growth funded by venture investors, not your balance sheet
- Pre-defined right to strategic re-engagement (license, partner, acquire)
For Investors & PE
- Access to pre-validated deep tech ventures — not raw deal flow
- Every venture arrives with: structured IP, tested market thesis, assembled founding team, clear governance
- mantro as co-founder and co-investor — permanent skin in the game
- Plug-and-play infrastructure: the venture is operational from day one
Track record
From stalled Merck R&D to a US-funded venture: MilliporeSigma — Merck's life-science arm — held a protein-membrane technology with applications across cultivated meat and plant-based food. The team had explored commercialization internally; it stalled at TRL 3–4. mantro structured the carve-out, negotiated the IP license, recruited the founding team from inside MilliporeSigma, incorporated the US entity, and ran the seed round externally. Merck retained an exclusive license and a strategic minority stake. EdiMembre is now Boston-based with active food-industry partnerships — and the relationship between Merck and mantro is open for additional carve-outs.
From stalled Merck R&D to a US-funded venture: MilliporeSigma — Merck's life-science arm — held a protein-membrane technology with applications across cultivated meat and plant-based food. The team had explored commercialization internally; it stalled at TRL 3–4. mantro structured the carve-out, negotiated the IP license, recruited the founding team from inside MilliporeSigma, incorporated the US entity, and ran the seed round externally. Merck retained an exclusive license and a strategic minority stake. EdiMembre is now Boston-based with active food-industry partnerships — and the relationship between Merck and mantro is open for additional carve-outs.
A carve-out isn't an exit.
It's how you build the next chapter of your company.
Get in touch
If you want to stress-test an idea, unblock an initiative, or simply see whether we're the right partner, let's talk. You can book a straight-to-the-point session with our CEO Manni, or leave us a message.
30-minute call. No strings attached.
